Clinical Trial Update: A First-in-human Study to Assess OT-C001 (Amplified/Activated Allogenic Natural Killer Cells) in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma [Phase 1]

View source ↗

Summary

This is a first-in-human Phase 1 trial evaluating OT-C001, amplified/activated allogeneic natural killer cells, in patients with relapsed/refractory diffuse lar…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• OT-C001 (Amplified/Activated Allogenic Natural Killer Cells)

Snippet

Sponsor: Emercell SAS | Conditions: Diffuse Large B-cell Lymphoma With no Other Specification | Phase 1 | Status: RECRUITING